Skip to main content

Peer Review reports

From: RUNX3 pathway signature predicts clinical benefits of immune checkpoint inhibition plus tyrosine kinase inhibition in advanced renal cell carcinoma

Original Submission
28 Mar 2023 Submitted Original manuscript
4 May 2023 Reviewed Reviewer Report - Francesk Mulita
9 May 2023 Reviewed Reviewer Report
4 Jul 2023 Author responded Author comments - Xianglai Xu
Resubmission - Version 2
4 Jul 2023 Submitted Manuscript version 2
6 Jul 2023 Author responded Author comments - Xianglai Xu
Resubmission - Version 3
6 Jul 2023 Submitted Manuscript version 3
19 Sep 2023 Reviewed Reviewer Report - Francesk Mulita
25 Sep 2023 Reviewed Reviewer Report
15 Oct 2023 Author responded Author comments - Xianglai Xu
Resubmission - Version 4
15 Oct 2023 Submitted Manuscript version 4
19 Oct 2023 Author responded Author comments - Xianglai Xu
Resubmission - Version 5
19 Oct 2023 Submitted Manuscript version 5
19 Oct 2023 Reviewed Reviewer Report - Francesk Mulita
31 Oct 2023 Reviewed Reviewer Report
Resubmission - Version 6
Submitted Manuscript version 6
Publishing
1 Nov 2023 Editorially accepted
3 Jan 2024 Article published 10.1186/s12894-023-01356-w

You can find further information about peer review here.

Back to article page